H.C. Wainwright analyst Oren Livnat says Lipocine yesterday reported “surprisingly strong” liver fat reduction interim data. The analyst reiterates a Buy rating on the shares with a $3 price target. The LPCN-1144 results could justify proceeding to a biopsy confirmed Phase 2a non-alcoholic steatohepatitis trial and inclusion of something for NASH in our valuation, Livnat tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.